{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T21:07:18Z","timestamp":1791493638555,"version":"4.3.4"},"reference-count":312,"publisher":"National Institute for Health and Care Research","issue":"76","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/www.nationalarchives.gov.uk\/doc\/non-commercial-government-licence\/non-commercial-government-licence.htm"}],"funder":[{"DOI":"10.13039\/501100000664","name":"Health Technology Assessment programme","doi-asserted-by":"publisher","award":["NIHR127852"],"award-info":[{"award-number":["NIHR127852"]}],"id":[{"id":"10.13039\/501100000664","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["journalslibrary.nihr.ac.uk"],"crossmark-restriction":false},"short-container-title":["Health Technol Assess"],"abstract":"\n Background<\/jats:title>\n The first histology-independent marketing authorisation in Europe was granted in 2019. This was the first time that a cancer treatment was approved based on a common biomarker rather than the location in the body at which the tumour originated. This research aims to explore the implications for National Institute for Health and Care Excellence appraisals.<\/jats:p>\n <\/jats:sec>\n \n Methods<\/jats:title>\n Targeted reviews were undertaken to determine the type of evidence that is likely to be available at the point of marketing authorisation and the analyses required to support National Institute for Health and Care Excellence appraisals. Several challenges were identified concerning the design and conduct of trials for histology-independent products, the greater levels of heterogeneity within the licensed population and the use of surrogate end points. We identified approaches to address these challenges by reviewing key statistical literature that focuses on the design and analysis of histology-independent trials and by undertaking a systematic review to evaluate the use of response end points as surrogate outcomes for survival end points. We developed a decision framework to help to inform approval and research policies for histology-independent products. The framework explored the uncertainties and risks associated with different approval policies, including the role of further data collection, pricing schemes and stratified decision-making.<\/jats:p>\n <\/jats:sec>\n \n Results<\/jats:title>\n We found that the potential for heterogeneity in treatment effects, across tumour types or other characteristics, is likely to be a central issue for National Institute for Health and Care Excellence appraisals. Bayesian hierarchical methods may serve as a useful vehicle to assess the level of heterogeneity across tumours and to estimate the pooled treatment effects for each tumour, which can inform whether or not the assumption of homogeneity is reasonable. Our review suggests that response end points may not be reliable surrogates for survival end points. However, a surrogate-based modelling approach, which captures all relevant uncertainty, may be preferable to the use of immature survival data. Several additional sources of heterogeneity were identified as presenting potential challenges to National Institute for Health and Care Excellence appraisal, including the cost of testing, baseline risk, quality of life and routine management costs. We concluded that a range of alternative approaches will be required to address different sources of heterogeneity to support National Institute for Health and Care Excellence appraisals. An exemplar case study was developed to illustrate the nature of the assessments that may be required.<\/jats:p>\n <\/jats:sec>\n \n Conclusions<\/jats:title>\n Adequately designed and analysed basket studies that assess the homogeneity of outcomes and allow borrowing of information across baskets, where appropriate, are recommended. Where there is evidence of heterogeneity in treatment effects and estimates of cost-effectiveness, consideration should be given to optimised recommendations. Routine presentation of the scale of the consequences of heterogeneity and decision uncertainty may provide an important additional approach to the assessments specified in the current National Institute for Health and Care Excellence methods guide.<\/jats:p>\n <\/jats:sec>\n \n Further research<\/jats:title>\n Further exploration of Bayesian hierarchical methods could help to inform decision-makers on whether or not there is sufficient evidence of homogeneity to support pooled analyses. Further research is also required to determine the appropriate basis for apportioning genomic testing costs where there are multiple targets and to address the challenges of uncontrolled Phase II studies, including the role and use of surrogate end points.<\/jats:p>\n <\/jats:sec>\n \n Funding<\/jats:title>\n \n This project was funded by the National Institute for Health Research (NIHR) Evidence Synthesis programme and will be published in full in\n Health Technology Assessment<\/jats:italic>\n ; Vol. 25, No. 76. See the NIHR Journals Library website for further project information.\n <\/jats:p>\n <\/jats:sec>","DOI":"10.3310\/hta25760","type":"journal-article","created":{"date-parts":[[2022,1,6]],"date-time":"2022-01-06T12:14:52Z","timestamp":1641471292000},"page":"1-228","update-policy":"https:\/\/doi.org\/10.3310\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":19,"title":["Modelling approaches for histology-independent cancer drugs to inform NICE appraisals: a systematic review and decision-framework"],"prefix":"10.3310","volume":"25","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-8864-1416","authenticated-orcid":true,"given":"Peter","family":"Murphy","sequence":"first","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0989-1984","authenticated-orcid":true,"given":"David","family":"Glynn","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2172-0221","authenticated-orcid":true,"given":"Sofia","family":"Dias","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6962-2893","authenticated-orcid":true,"given":"Robert","family":"Hodgson","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1795-7568","authenticated-orcid":true,"given":"Lindsay","family":"Claxton","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6803-5566","authenticated-orcid":true,"given":"Lucy","family":"Beresford","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7702-8103","authenticated-orcid":true,"given":"Katy","family":"Cooper","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6612-2332","authenticated-orcid":true,"given":"Paul","family":"Tappenden","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4284-217X","authenticated-orcid":true,"given":"Kate","family":"Ennis","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7211-438X","authenticated-orcid":true,"given":"Alessandro","family":"Grosso","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9020-1572","authenticated-orcid":true,"given":"Kath","family":"Wright","sequence":"additional","affiliation":[{"name":"Centre for Reviews and Dissemination, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0040-9853","authenticated-orcid":true,"given":"Anna","family":"Cantrell","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-3099-9877","authenticated-orcid":true,"given":"Matt","family":"Stevenson","sequence":"additional","affiliation":[{"name":"School of Health and Related Research (ScHARR) Technology Assessment Group, University of Sheffield, Sheffield, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7268-2560","authenticated-orcid":true,"given":"Stephen","family":"Palmer","sequence":"additional","affiliation":[{"name":"Centre for Health Economics, University of York, York, UK"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"6221","published-online":{"date-parts":[[2021,12]]},"reference":[{"key":"key20211223115343472_ref1-bib1","unstructured":"US Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Approval Package for Application Number 125514Orig1s014. Trade Name: Keytruda. Generic or Proper Name: Pembrolizumab. Rockville, MD: FDA; 2017."},{"key":"key20211223115343472_ref1-bib2","unstructured":"European Medicines Agency (EMA). Assessment Report: VITRAKVI. International Non-Proprietary Name: Larotrectinib. Amsterdam: EMA; 2019."},{"key":"key20211223115343472_ref1-bib3","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1056\/NEJMoa1714448","article-title":"Efficacy of Larotrectinib in TRK fusion-positive cancers in adults and children","volume":"378","author":"Drilon","year":"2018","journal-title":"N Engl J Med"},{"key":"key20211223115343472_ref1-bib4","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Methods of Technology Appraisal. London: NICE; 2013."},{"key":"key20211223115343472_ref1-bib5","unstructured":"U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease. Guidance for Industry. Silver Spring, MD: FDA; 2018."},{"key":"key20211223115343472_ref1-bib6","unstructured":"U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research, Oncology Center of Excellence. Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics. Guidance for Industry. Silver Spring, MD: FDA; 2018."},{"key":"key20211223115343472_ref1-bib7","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/0197-2456(89)90015-9","article-title":"Optimal two-stage designs for phase II clinical trials","volume":"10","author":"Simon","year":"1989","journal-title":"Control Clin Trials"},{"key":"key20211223115343472_ref1-bib8","unstructured":"U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research. Guidance for Industry Expedited Programs for Serious Conditions \u2013 Drugs and Biologics. Silver Spring, MD: FDA; 2014."},{"key":"key20211223115343472_ref1-bib9","unstructured":"U.S. Food and Drug Administration (FDA). Drug Approval Package: Vitrakvi (Larotrectinib). Rockville, MD: FDA; 2018. URL: www.accessdata.fda.gov\/drugsatfda_docs\/nda\/2018\/210861Orig1s000_21171Orig1s000TOC.cfm (accessed 17 January 2020)."},{"key":"key20211223115343472_ref1-bib10","unstructured":"U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research. Approval Package for Application Number 212725Orig1s000, 212726Orig1s000. Trade Name: ROZLYTREK\u00ae Capsules, 100 mg and 200 mg (Entrectinib). Rockville, MD: FDA; 2019."},{"key":"key20211223115343472_ref1-bib11","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1016\/j.mayocp.2016.02.012","article-title":"Strength of validation for surrogate end points used in the US Food and Drug Administration\u2019s approval of oncology drugs","volume":"91","author":"Kim","year":"2016","journal-title":"Mayo Clin Proc"},{"key":"key20211223115343472_ref1-bib12","doi-asserted-by":"publisher","first-page":"271","DOI":"10.1016\/S1470-2045(19)30691-6","article-title":"Entrectinib in patients with advanced or metastatic NTRK fusion-positive solid tumours: integrated analysis of three phase 1-2 trials","volume":"21","author":"Doebele","year":"2020","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib13","unstructured":"European Medicines Agency (EMA). Workshop on Site and Histology - Independent Indications in Oncology. Amsterdam: EMA; 2017. URL: www.ema.europa.eu\/en\/events\/workshop-site-histology-independent-indications-oncology (accessed 17 January 2020)."},{"key":"key20211223115343472_ref1-bib14","unstructured":"European Medicines Agency (EMA). Workshop on Single-arm Trials in Oncology. Amsterdam: EMA; 2016. URL: www.ema.europa.eu\/en\/events\/workshop-single-arm-trials-oncology (accessed 17 January 2020)."},{"key":"key20211223115343472_ref1-bib15","unstructured":"European Medicines Agency (EMA). Guideline on the Evaluation of Anticancer Medicinal Products in Man. Amsterdam: EMA; 2017."},{"key":"key20211223115343472_ref1-bib16","unstructured":"European Medicines Agency (EMA). Concept Paper on the Revision of the Guideline on the Evaluation of Anticancer Medicinal Products in Man. Amsterdam: EMA; 2018."},{"key":"key20211223115343472_ref1-bib17","doi-asserted-by":"publisher","first-page":"705","DOI":"10.1016\/S1470-2045(18)30119-0","article-title":"Larotrectinib for paediatric solid tumours harbouring NTRK fusions: phase 1 results from a multicentre, open-label, phase 1\/2 study","volume":"19","author":"Laetsch","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib18","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1016\/0021-9681(61)90060-1","article-title":"The determination of the number of patients required in a preliminary and a follow-up trial of a new chemotherapeutic agent","volume":"13","author":"Gehan","year":"1961","journal-title":"J Chronic Dis"},{"key":"key20211223115343472_ref1-bib19","doi-asserted-by":"publisher","first-page":"143","DOI":"10.2307\/2530297","article-title":"One-sample multiple testing procedure for phase II clinical trial","volume":"38","author":"Fleming","year":"1982","journal-title":"Biometrics"},{"key":"key20211223115343472_ref1-bib20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1111\/j.0006-341X.2004.00193.x","article-title":"Adaptive two-stage designs for single-arm phase IIA cancer clinical trials","volume":"60","author":"Lin","year":"2004","journal-title":"Biometrics"},{"key":"key20211223115343472_ref1-bib21","doi-asserted-by":"publisher","first-page":"775","DOI":"10.2307\/2530109","article-title":"Predictive probability early termination plans for phase II clinical trials","volume":"35","author":"Herson","year":"1979","journal-title":"Biometrics"},{"key":"key20211223115343472_ref1-bib22","doi-asserted-by":"publisher","first-page":"337","DOI":"10.2307\/2533377","article-title":"Practical Bayesian guidelines for phase IIB clinical trials","volume":"50","author":"Thall","year":"1994","journal-title":"Biometrics"},{"key":"key20211223115343472_ref1-bib23","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/(SICI)1097-0258(19970830)16:16<1791::AID-SIM609>3.0.CO;2-E","article-title":"Bayesian interim analysis of phase II cancer clinical trials","volume":"16","author":"Heitjan","year":"1997","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib24","doi-asserted-by":"publisher","first-page":"1991","DOI":"10.1002\/sim.1176","article-title":"Bayesian two-stage designs for phase II clinical trials","volume":"21","author":"Tan","year":"2002","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib25","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/s41416-019-0653-9","article-title":"Effective delivery of Complex Innovative Design (CID) cancer trials \u2013 a consensus statement","volume":"122","author":"Blagden","year":"2020","journal-title":"Br J Cancer"},{"key":"key20211223115343472_ref1-bib26","doi-asserted-by":"publisher","first-page":"975","DOI":"10.1200\/JCO.2014.59.8433","article-title":"Basket trials and the evolution of clinical trial design in an era of genomic medicine","volume":"33","author":"Redig","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib27","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1093\/annonc\/mdw413","article-title":"Statistical controversies in clinical research: basket trials, umbrella trials, and other master protocols: a review and examples","volume":"28","author":"Renfro","year":"2017","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib28","doi-asserted-by":"publisher","first-page":"584","DOI":"10.1016\/j.cell.2016.12.015","article-title":"Implementing genome-driven oncology","volume":"168","author":"Hyman","year":"2017","journal-title":"Cell"},{"key":"key20211223115343472_ref1-bib29","doi-asserted-by":"publisher","first-page":"217","DOI":"10.1080\/10543406.2017.1372778","article-title":"Definitions and statistical properties of master protocols for personalized medicine in oncology","volume":"28","author":"Renfro","year":"2018","journal-title":"J Biopharm Stat"},{"key":"key20211223115343472_ref1-bib30","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1080\/10543406.2017.1372779","article-title":"New designs for basket clinical trials in oncology","volume":"28","author":"Simon","year":"2018","journal-title":"J Biopharm Stat"},{"key":"key20211223115343472_ref1-bib31","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1200\/JCO.2014.58.2007","article-title":"Molecular profiling and targeted therapy for advanced thoracic malignancies: a biomarker-derived, multiarm, multihistology phase II basket trial","volume":"33","author":"Lopez-Chavez","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib32","doi-asserted-by":"publisher","first-page":"726","DOI":"10.1056\/NEJMoa1502309","article-title":"Vemurafenib in multiple nonmelanoma cancers with BRAF V600 mutations","volume":"373","author":"Hyman","year":"2015","journal-title":"N Engl J Med"},{"key":"key20211223115343472_ref1-bib33","doi-asserted-by":"publisher","first-page":"1324","DOI":"10.1016\/S1470-2045(15)00188-6","article-title":"Molecularly targeted therapy based on tumour molecular profiling versus conventional therapy for advanced cancer (SHIVA): a multicentre, open-label, proof-of-concept, randomised, controlled phase 2 trial","volume":"16","author":"Le Tourneau","year":"2015","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib34","doi-asserted-by":"publisher","first-page":"617","DOI":"10.1002\/cpt.446","article-title":"Adaptive design for a confirmatory basket trial in multiple tumor types based on a putative predictive biomarker","volume":"100","author":"Beckman","year":"2016","journal-title":"Clin Pharmacol Ther"},{"key":"key20211223115343472_ref1-bib35","volume-title":"Platform Trial Designs in Drug Development: Umbrella Trials and Basket Trials","author":"Antonijevic","year":"2019"},{"key":"key20211223115343472_ref1-bib36","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1158\/1078-0432.CCR-12-1223","article-title":"Borrowing information across subgroups in phase II trials: is it useful?","volume":"19","author":"Freidlin","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20211223115343472_ref1-bib37","doi-asserted-by":"publisher","first-page":"934","DOI":"10.1002\/cpt.814","article-title":"Critical review of umbrella, basket, and platform designs for oncology clinical trials","volume":"102","author":"Simon","year":"2017","journal-title":"Clin Pharmacol Ther"},{"key":"key20211223115343472_ref1-bib38","first-page":"167","volume-title":"Platform Trials in Drug Development: Umbrella Trials and Basket Trials","author":"Simon","year":"2019"},{"key":"key20211223115343472_ref1-bib39","doi-asserted-by":"publisher","first-page":"2597","DOI":"10.1002\/sim.2139","article-title":"One- and two-stage designs for stratified phase II clinical trials","volume":"24","author":"London","year":"2005","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib40","doi-asserted-by":"publisher","first-page":"4256","DOI":"10.1158\/1078-0432.CCR-08-2069","article-title":"Multiple histology phase II trials","volume":"15","author":"Leblanc","year":"2009","journal-title":"Clin Cancer Res"},{"key":"key20211223115343472_ref1-bib41","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1080\/10543406.2010.536873","article-title":"Phase II cancer clinical trials with heterogeneous patient populations","volume":"22","author":"Jung","year":"2012","journal-title":"J Biopharm Stat"},{"key":"key20211223115343472_ref1-bib42","doi-asserted-by":"publisher","first-page":"1568","DOI":"10.1002\/sim.7227","article-title":"An efficient basket trial design","volume":"36","author":"Cunanan","year":"2017","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib43","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1053\/j.seminoncol.2016.01.002","article-title":"The Bayesian basket design for genomic variant-driven phase II trials","volume":"43","author":"Simon","year":"2016","journal-title":"Semin Oncol"},{"key":"key20211223115343472_ref1-bib44","doi-asserted-by":"publisher","first-page":"449","DOI":"10.1101\/401620","article-title":"Comparing the efficacy of cancer therapies between subgroups in basket trials","volume":"11","author":"Palmer","year":"2020","journal-title":"Cell Syst"},{"key":"key20211223115343472_ref1-bib45","volume-title":"Bayesian Approaches to Clinical Trials and Health-Care Evaluation","author":"Spiegelhalter","year":"2004"},{"key":"key20211223115343472_ref1-bib46","doi-asserted-by":"publisher","first-page":"763","DOI":"10.1002\/sim.1399","article-title":"Hierarchical Bayesian approaches to phase II trials in diseases with multiple subtypes","volume":"22","author":"Thall","year":"2003","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib47","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1002\/(SICI)1097-0258(19980730)17:14%3C1563::AID-SIM873%3E3.0.CO;2-L","article-title":"Some extensions and applications of a Bayesian strategy for monitoring multiple outcomes in clinical trials","volume":"17","author":"Thall","year":"1998","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib48","doi-asserted-by":"publisher","first-page":"3148","DOI":"10.1200\/JCO.2008.20.5054","article-title":"Phase II multicenter trial of imatinib in 10 histologic subtypes of sarcoma using a Bayesian hierarchical statistical model","volume":"27","author":"Chugh","year":"2009","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib49","doi-asserted-by":"publisher","first-page":"720","DOI":"10.1177\/1740774513497539","article-title":"Bayesian hierarchical modeling of patient subpopulations: efficient designs of Phase II oncology clinical trials","volume":"10","author":"Berry","year":"2013","journal-title":"Clin Trials"},{"key":"key20211223115343472_ref1-bib50","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/j.cct.2017.06.009","article-title":"Increasing the efficiency of oncology basket trials using a Bayesian approach","volume":"63","author":"Liu","year":"2017","journal-title":"Contemp Clin Trials"},{"key":"key20211223115343472_ref1-bib51","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1002\/pst.1730","article-title":"Robust exchangeability designs for early phase clinical trials with multiple strata","volume":"15","author":"Neuenschwander","year":"2016","journal-title":"Pharm Stat"},{"key":"key20211223115343472_ref1-bib52","doi-asserted-by":"publisher","first-page":"142","DOI":"10.1177\/1740774518812779","article-title":"Variance prior specification for a basket trial design using Bayesian hierarchical modeling","volume":"16","author":"Cunanan","year":"2019","journal-title":"Clin Trials"},{"key":"key20211223115343472_ref1-bib53","doi-asserted-by":"publisher","first-page":"550","DOI":"10.1111\/j.1541-0420.2011.01693.x","article-title":"Borrowing strength with nonexchangeable priors over subpopulations","volume":"68","author":"Leon-Novelo","year":"2012","journal-title":"Biometrics"},{"key":"key20211223115343472_ref1-bib54","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1111\/rssc.12255","article-title":"BLAST: Bayesian latent subgroup design for basket trials accounting for patient heterogeneity","volume":"67","author":"Chu","year":"2018","journal-title":"J R Stat Soc Ser C Appl Stat"},{"key":"key20211223115343472_ref1-bib55","doi-asserted-by":"publisher","first-page":"149","DOI":"10.1177\/1740774518755122","article-title":"A Bayesian basket trial design using a calibrated Bayesian hierarchical model","volume":"15","author":"Chu","year":"2018","journal-title":"Clin Trials"},{"key":"key20211223115343472_ref1-bib56","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1002\/bimj.201800404","article-title":"A Bayesian basket trial design that borrows information across strata based on the similarity between the posterior distributions of the response probability","volume":"62","author":"Fujikawa","year":"2020","journal-title":"Biom J"},{"key":"key20211223115343472_ref1-bib57","doi-asserted-by":"publisher","first-page":"3557","DOI":"10.1002\/sim.7893","article-title":"Bayesian basket trial design with exchangeability monitoring","volume":"37","author":"Hobbs","year":"2018","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib58","doi-asserted-by":"publisher","first-page":"809","DOI":"10.1056\/NEJMoa1002011","article-title":"Inhibition of mutated, activated BRAF in metastatic melanoma","volume":"363","author":"Flaherty","year":"2010","journal-title":"N Engl J Med"},{"key":"key20211223115343472_ref1-bib59","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1038\/nature10868","article-title":"Unresponsiveness of colon cancer to BRAF(V600E) inhibition through feedback activation of EGFR","volume":"483","author":"Prahallad","year":"2012","journal-title":"Nature"},{"key":"key20211223115343472_ref1-bib60","doi-asserted-by":"publisher","first-page":"2717","DOI":"10.1158\/1078-0432.CCR-07-4575","article-title":"Phase II, open-label study evaluating the activity of imatinib in treating life-threatening malignancies known to be associated with imatinib-sensitive tyrosine kinases","volume":"14","author":"Heinrich","year":"2008","journal-title":"Clin Cancer Res"},{"key":"key20211223115343472_ref1-bib61","doi-asserted-by":"publisher","first-page":"39","DOI":"10.1056\/NEJMra043186","article-title":"Trastuzumab \u2013 mechanism of action and use in clinical practice","volume":"357","author":"Hudis","year":"2007","journal-title":"N Engl J Med"},{"key":"key20211223115343472_ref1-bib62","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1016\/j.ygyno.2009.09.025","article-title":"Phase II trial of trastuzumab in women with advanced or recurrent, HER2-positive endometrial carcinoma: a Gynecologic Oncology Group study","volume":"116","author":"Fleming","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20211223115343472_ref1-bib63","doi-asserted-by":"publisher","first-page":"19","DOI":"10.1093\/annonc\/mdh031","article-title":"Randomized phase II trial of gemcitabine-cisplatin with or without trastuzumab in HER2-positive non-small-cell lung cancer","volume":"15","author":"Gatzemeier","year":"2004","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib64","doi-asserted-by":"publisher","first-page":"1686","DOI":"10.1038\/s41416-020-01050-w","article-title":"A systematic review of meta-analyses assessing the validity of tumour response endpoints as surrogates for progression-free or overall survival in cancer","volume":"123","author":"Cooper","year":"2020","journal-title":"Br J Cancer"},{"key":"key20211223115343472_ref1-bib65","doi-asserted-by":"publisher","first-page":"2973","DOI":"10.1002\/sim.5403","article-title":"Biomarkers and surrogate endpoints in clinical trials","volume":"31","author":"Fleming","year":"2012","journal-title":"Stat Med"},{"issue":"8","key":"key20211223115343472_ref1-bib66","doi-asserted-by":"publisher","DOI":"10.3310\/hta13080","article-title":"The use of surrogate outcomes in model-based cost-effectiveness analyses: a survey of UK Health Technology Assessment reports","volume":"13","author":"Taylor","year":"2009","journal-title":"Health Technol Assess"},{"key":"key20211223115343472_ref1-bib67","doi-asserted-by":"publisher","first-page":"605","DOI":"10.7326\/0003-4819-125-7-199610010-00011","article-title":"Surrogate end points in clinical trials: are we being misled?","volume":"125","author":"Fleming","year":"1996","journal-title":"Ann Intern Med"},{"key":"key20211223115343472_ref1-bib68","doi-asserted-by":"publisher","first-page":"431","DOI":"10.1002\/sim.4780080407","article-title":"Surrogate endpoints in clinical trials: definition and operational criteria","volume":"8","author":"Prentice","year":"1989","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib69","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1093\/biostatistics\/1.1.49","article-title":"The validation of surrogate endpoints in meta-analyses of randomized experiments","volume":"1","author":"Buyse","year":"2000","journal-title":"Biostatistics"},{"key":"key20211223115343472_ref1-bib70","doi-asserted-by":"publisher","first-page":"2012","DOI":"10.1093\/annonc\/mdv333","article-title":"Statistical controversies in clinical research: an initial evaluation of a surrogate end point using a single randomized clinical trial and the Prentice criteria","volume":"26","author":"Heller","year":"2015","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib71","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1067\/mcp.2001.113989","article-title":"Biomarkers and surrogate endpoints: preferred definitions and conceptual framework","volume":"69","author":"Biomarkers Definitions Working Group","year":"2001","journal-title":"Clin Pharmacol Ther"},{"key":"key20211223115343472_ref1-bib72","doi-asserted-by":"publisher","first-page":"771","DOI":"10.1001\/jama.282.8.771","article-title":"Users\u2019 guides to the medical literature: XIX. Applying clinical trial results. A. How to use an article measuring the effect of an intervention on surrogate end points","volume":"282","author":"Bucher","year":"1999","journal-title":"JAMA"},{"key":"key20211223115343472_ref1-bib73","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1017\/S0266462309090023","article-title":"Use of surrogate outcomes in cost-effectiveness models: a review of United Kingdom health technology assessment reports","volume":"25","author":"Elston","year":"2009","journal-title":"Int J Technol Assess Health Care"},{"key":"key20211223115343472_ref1-bib74","unstructured":"German Institute of Quality and Efficiency in Health Care (IQWiG). Validity of Surrogate Endpoints in Oncology. Cologne: IQWiG; 2011."},{"key":"key20211223115343472_ref1-bib75","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1471-2288-12-27","article-title":"Is blood pressure reduction a valid surrogate endpoint for stroke prevention? An analysis incorporating a systematic review of randomised controlled trials, a by-trial weighted errors-in-variables regression, the surrogate threshold effect (STE) and the Biomarker-Surrogacy (BioSurrogate) Evaluation Schema (BSES)","volume":"12","author":"Lassere","year":"2012","journal-title":"BMC Med Res Methodol"},{"key":"key20211223115343472_ref1-bib76","doi-asserted-by":"publisher","first-page":"104","DOI":"10.1002\/bimj.201400049","article-title":"Statistical evaluation of surrogate endpoints with examples from cancer clinical trials","volume":"58","author":"Buyse","year":"2016","journal-title":"Biom J"},{"key":"key20211223115343472_ref1-bib77","volume-title":"Extrapolation from Progression-Free Survival to Overall Survival in Oncology","author":"Fischer","year":"2016"},{"key":"key20211223115343472_ref1-bib78","volume-title":"A Review of Studies Examining the Relationship Between Progression-free Survival and Overall Survival in Advanced or Metastatic Cancer","author":"Davis","year":"2012"},{"key":"key20211223115343472_ref1-bib79","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1016\/j.critrevonc.2017.11.014","article-title":"Meta-analyses evaluating surrogate endpoints for overall survival in cancer randomized trials: a critical review","volume":"123","author":"Savina","year":"2018","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20211223115343472_ref1-bib80","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1016\/j.ejca.2018.11.012","article-title":"A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology","volume":"106","author":"Haslam","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20211223115343472_ref1-bib81","doi-asserted-by":"publisher","first-page":"139","DOI":"10.2217\/imt-2017-0115","article-title":"Surrogate end points for overall survival in trials of PD-(L)1 inhibitors for urinary cancers: a systematic review","volume":"10","author":"Abdel-Rahman","year":"2018","journal-title":"Immunotherapy"},{"key":"key20211223115343472_ref1-bib82","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.clgc.2013.09.002","article-title":"Six-month progression-free survival as the primary endpoint to evaluate the activity of new agents as second-line therapy for advanced urothelial carcinoma","volume":"12","author":"Agarwal","year":"2014","journal-title":"Clin Genitourin Cancer"},{"key":"key20211223115343472_ref1-bib83","doi-asserted-by":"publisher","first-page":"1562","DOI":"10.7150\/jca.18686","article-title":"Response rates as predictors of overall survival: a meta-analysis of acute myeloid leukemia trials","volume":"8","author":"Agarwal","year":"2017","journal-title":"J Cancer"},{"key":"key20211223115343472_ref1-bib84","doi-asserted-by":"publisher","first-page":"1008","DOI":"10.1200\/JCO.2014.59.0489","article-title":"Overall response rate, progression-free survival, and overall survival with targeted and standard therapies in advanced non-small-cell lung cancer: US Food and Drug Administration trial-level and patient-level analyses","volume":"33","author":"Blumenthal","year":"2015","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib85","doi-asserted-by":"publisher","first-page":"e171029","DOI":"10.1001\/jamaoncol.2017.1029","article-title":"Milestone analyses of immune checkpoint inhibitors, targeted therapy, and conventional therapy in metastatic non-small cell lung cancer trials: a meta-analysis","volume":"3","author":"Blumenthal","year":"2017","journal-title":"JAMA Oncol"},{"key":"key20211223115343472_ref1-bib86","doi-asserted-by":"publisher","first-page":"5117","DOI":"10.1200\/JCO.2005.02.106","article-title":"Objective response to chemotherapy as a potential surrogate end point of survival in metastatic breast cancer patients","volume":"23","author":"Bruzzi","year":"2005","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib87","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1200\/JCO.2007.10.8407","article-title":"Evaluation of tumor response, disease control, progression-free survival, and time to progression as potential surrogate end points in metastatic breast cancer","volume":"26","author":"Burzykowski","year":"2008","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib88","doi-asserted-by":"publisher","first-page":"373","DOI":"10.1016\/S0140-6736(00)02528-9","article-title":"Relation between tumour response to first-line chemotherapy and survival in advanced colorectal cancer: a meta-analysis. Meta-Analysis Group in Cancer","volume":"356","author":"Buyse","year":"2000","journal-title":"Lancet"},{"key":"key20211223115343472_ref1-bib89","doi-asserted-by":"publisher","first-page":"833","DOI":"10.1016\/j.jclinepi.2015.02.016","article-title":"Meta-analyses of randomized controlled trials show suboptimal validity of surrogate outcomes for overall survival in advanced colorectal cancer","volume":"68","author":"Ciani","year":"2015","journal-title":"J Clin Epidemiol"},{"key":"key20211223115343472_ref1-bib90","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1007\/s12032-017-0939-9","article-title":"Trial-level analysis of progression-free survival and response rate as end points of trials of first-line chemotherapy in advanced ovarian cancer","volume":"34","author":"Colloca","year":"2017","journal-title":"Med Oncol"},{"key":"key20211223115343472_ref1-bib91","doi-asserted-by":"publisher","first-page":"264","DOI":"10.1016\/j.clcc.2015.11.006","article-title":"Analysis of response-related and time-to-event endpoints in randomized trials of gemcitabine-based treatment versus gemcitabine alone as first-line treatment of patients with advanced pancreatic cancer","volume":"15","author":"Colloca","year":"2016","journal-title":"Clin Colorectal Cancer"},{"key":"key20211223115343472_ref1-bib92","doi-asserted-by":"publisher","first-page":"e155","DOI":"10.1016\/j.clon.2016.05.001","article-title":"Analysis of clinical end points of randomised trials including bevacizumab and chemotherapy versus chemotherapy as first-line treatment of metastatic colorectal cancer","volume":"28","author":"Colloca","year":"2016","journal-title":"Clin Oncol"},{"key":"key20211223115343472_ref1-bib93","doi-asserted-by":"publisher","first-page":"389","DOI":"10.1016\/j.clgc.2016.03.022","article-title":"Trial level analysis of prostate-specific antigen-related versus unrelated endpoints in phase III trials of first-line and second-line medical treatments of patients with metastatic castration-resistant prostate cancer","volume":"14","author":"Colloca","year":"2016","journal-title":"Clin Genitourin Cancer"},{"key":"key20211223115343472_ref1-bib94","doi-asserted-by":"publisher","first-page":"834","DOI":"10.4143\/crt.2016.249","article-title":"Surrogate endpoints in second-line trials of targeted agents in metastatic colorectal cancer: a literature-based systematic review and meta-analysis","volume":"49","author":"Cremolini","year":"2017","journal-title":"Cancer Res Treat"},{"key":"key20211223115343472_ref1-bib95","doi-asserted-by":"publisher","first-page":"1059","DOI":"10.1038\/bjc.2012.367","article-title":"Association between treatment effects on disease progression end points and overall survival in clinical studies of patients with metastatic renal cell carcinoma","volume":"107","author":"Delea","year":"2012","journal-title":"Br J Cancer"},{"key":"key20211223115343472_ref1-bib96","doi-asserted-by":"publisher","first-page":"101665","DOI":"10.1016\/j.canep.2019.101665","article-title":"Combining tumour response and progression free survival as surrogate endpoints for overall survival in advanced colorectal cancer","volume":"64","author":"Elia","year":"2020","journal-title":"Cancer Epidemiol"},{"key":"key20211223115343472_ref1-bib97","doi-asserted-by":"publisher","first-page":"1262","DOI":"10.1002\/cncr.25526","article-title":"Tumor response and progression-free survival as potential surrogate endpoints for overall survival in extensive stage small-cell lung cancer: findings on the basis of North Central Cancer Treatment Group trials","volume":"117","author":"Foster","year":"2011","journal-title":"Cancer"},{"key":"key20211223115343472_ref1-bib98","doi-asserted-by":"publisher","first-page":"187","DOI":"10.3109\/0284186X.2014.938830","article-title":"Surrogate endpoints in second-line treatment for mCRC: a systematic literature-based analysis from 23 randomised trials","volume":"54","author":"Giessen","year":"2015","journal-title":"Acta Oncol"},{"key":"key20211223115343472_ref1-bib99","doi-asserted-by":"publisher","first-page":"1215","DOI":"10.1038\/sj.bjc.6602858","article-title":"Surrogate markers and survival in women receiving first-line combination anthracycline chemotherapy for advanced breast cancer","volume":"93","author":"Hackshaw","year":"2005","journal-title":"Br J Cancer"},{"key":"key20211223115343472_ref1-bib100","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1016\/j.ejca.2016.05.016","article-title":"Progression-free survival as a surrogate for overall survival in first-line chemotherapy for advanced pancreatic cancer","volume":"65","author":"Hamada","year":"2016","journal-title":"Eur J Cancer"},{"key":"key20211223115343472_ref1-bib101","doi-asserted-by":"publisher","first-page":"696","DOI":"10.1093\/neuonc\/not236","article-title":"Progression-free survival as a surrogate endpoint for overall survival in glioblastoma: a literature-based meta-analysis from 91 trials","volume":"16","author":"Han","year":"2014","journal-title":"Neuro Oncol"},{"key":"key20211223115343472_ref1-bib102","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.jval.2017.07.011","article-title":"Do surrogate endpoints better correlate with overall survival in studies that did not allow for crossover or reported balanced postprogression treatments? An application in advanced non-small cell lung cancer","volume":"21","author":"Hashim","year":"2018","journal-title":"Value Health"},{"key":"key20211223115343472_ref1-bib103","doi-asserted-by":"publisher","first-page":"e0121211","DOI":"10.1371\/journal.pone.0121211","article-title":"Magnitude of the benefit of progression-free survival as a potential surrogate marker in phase 3 trials assessing targeted agents in molecularly selected patients with advanced non-small cell lung cancer: systematic review","volume":"10","author":"Hotta","year":"2015","journal-title":"PLOS ONE"},{"key":"key20211223115343472_ref1-bib104","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1093\/annonc\/mdp020","article-title":"Association between incremental gains in the objective response rate and survival improvement in phase III trials of first-line chemotherapy for extensive disease small-cell lung cancer","volume":"20","author":"Hotta","year":"2009","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib105","doi-asserted-by":"publisher","first-page":"1665","DOI":"10.1093\/annonc\/mdl174","article-title":"Correlation between tumor response to first-line chemotherapy and prognosis in advanced gastric cancer patients","volume":"17","author":"Ichikawa","year":"2006","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib106","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1530\/ERC-17-0197","article-title":"Progression-free survival as a surrogate endpoint in advanced neuroendocrine neoplasms","volume":"24","author":"Imaoka","year":"2017","journal-title":"Endocr Relat Cancer"},{"key":"key20211223115343472_ref1-bib107","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1634\/theoncologist.2017-0651","article-title":"Alternate endpoints for phase II trials in advanced neuroendocrine tumors","volume":"24","author":"Imaoka","year":"2019","journal-title":"Oncologist"},{"key":"key20211223115343472_ref1-bib108","doi-asserted-by":"publisher","first-page":"1285","DOI":"10.1007\/s00330-018-5692-8","article-title":"TACE with degradable starch microspheres (DSM-TACE) as second-line treatment in HCC patients dismissing or ineligible for sorafenib","volume":"29","author":"Iezzi","year":"2019","journal-title":"Eur Radiol"},{"key":"key20211223115343472_ref1-bib109","doi-asserted-by":"publisher","first-page":"741","DOI":"10.1016\/S1470-2045(06)70800-2","article-title":"Response rate or time to progression as predictors of survival in trials of metastatic colorectal cancer or non-small-cell lung cancer: a meta-analysis","volume":"7","author":"Johnson","year":"2006","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib110","doi-asserted-by":"publisher","first-page":"2245","DOI":"10.1007\/s00432-018-2738-x","article-title":"Evaluation of classical clinical endpoints as surrogates for overall survival in patients treated with immune checkpoint blockers: a systematic review and meta-analysis","volume":"144","author":"Kaufman","year":"2018","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20211223115343472_ref1-bib111","doi-asserted-by":"publisher","first-page":"1392","DOI":"10.1093\/annonc\/mdq615","article-title":"Identification of potential surrogate end points in randomized clinical trials of aggressive and indolent non-Hodgkin\u2019s lymphoma: correlation of complete response, time-to-event and overall survival end points","volume":"22","author":"Lee","year":"2011","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib112","doi-asserted-by":"publisher","first-page":"1623","DOI":"10.2147\/CMAR.S188551","article-title":"Complete response associated with immune checkpoint inhibitors in advanced non-small-cell lung cancer: a meta-analysis of nine randomized controlled trials","volume":"11","author":"Li","year":"2019","journal-title":"Cancer Manag Res"},{"key":"key20211223115343472_ref1-bib113","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1007\/s00432-012-1278-z","article-title":"Surrogate end points for survival in the target treatment of advanced non-small-cell lung cancer with gefitinib or erlotinib","volume":"138","author":"Li","year":"2012","journal-title":"J Cancer Res Clin Oncol"},{"key":"key20211223115343472_ref1-bib114","doi-asserted-by":"publisher","first-page":"336","DOI":"10.1016\/j.bulcan.2016.01.002","article-title":"Correlation between overall survival and other endpoints in metastatic breast cancer with second- or third-line chemotherapy: literature-based analysis of 24 randomized trials","volume":"103","author":"Liu","year":"2016","journal-title":"Bull Cancer"},{"key":"key20211223115343472_ref1-bib115","doi-asserted-by":"publisher","first-page":"2033","DOI":"10.1002\/1097-0142(20010601)91:11<2033::AID-CNCR1229>3.0.CO;2-J","article-title":"Correlation between progression free survival and response rate in patients with metastatic colorectal carcinoma","volume":"91","author":"Louvet","year":"2001","journal-title":"Cancer"},{"key":"key20211223115343472_ref1-bib116","doi-asserted-by":"publisher","first-page":"2371","DOI":"10.1245\/s10434-017-5826-2","article-title":"Surrogate end points for overall survival in metastatic, locally advanced, or unresectable pancreatic cancer: a systematic review and meta-analysis of 24 randomized controlled trials","volume":"24","author":"Makris","year":"2017","journal-title":"Ann Surg Oncol"},{"key":"key20211223115343472_ref1-bib117","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1002\/hon.2463","article-title":"Relationship between response rates and median progression-free survival in non-Hodgkin\u2019s lymphoma: a meta-analysis of published clinical trials","volume":"36","author":"Mangal","year":"2018","journal-title":"Hematol Oncol"},{"key":"key20211223115343472_ref1-bib118","doi-asserted-by":"publisher","first-page":"547","DOI":"10.1002\/hon.2514","article-title":"Use of depth of response to predict progression-free survival in relapsed or refractory multiple myeloma: evaluation of results from 102 clinical trials","volume":"36","author":"Mangal","year":"2018","journal-title":"Hematol Oncol"},{"key":"key20211223115343472_ref1-bib119","doi-asserted-by":"publisher","first-page":"881","DOI":"10.1038\/bjc.2016.83","article-title":"Correlations of survival with progression-free survival, response rate, and disease control rate in advanced biliary tract cancer: a meta-analysis of randomised trials of first-line chemotherapy","volume":"114","author":"Moriwaki","year":"2016","journal-title":"Br J Cancer"},{"key":"key20211223115343472_ref1-bib120","doi-asserted-by":"publisher","first-page":"2268","DOI":"10.1158\/1078-0432.CCR-17-1902","article-title":"Evaluation of overall response rate and progression-free survival as potential surrogate endpoints for overall survival in immunotherapy trials","volume":"24","author":"Mushti","year":"2018","journal-title":"Clin Cancer Res"},{"key":"key20211223115343472_ref1-bib121","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1016\/j.jtho.2016.04.025","article-title":"Progression-free survival, response rate, and disease control rate as predictors of overall survival in phase III randomized controlled trials evaluating the first-line chemotherapy for advanced, locally advanced, and recurrent non-small cell lung carcinoma","volume":"11","author":"Nakashima","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20211223115343472_ref1-bib122","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1016\/j.cllc.2013.12.001","article-title":"Clinical trial design in small cell lung cancer: surrogate end points and statistical evolution","volume":"15","author":"Nickolich","year":"2014","journal-title":"Clin Lung Cancer"},{"key":"key20211223115343472_ref1-bib123","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1016\/j.ejca.2018.10.011","article-title":"Evaluation of objective response, disease control and progression-free survival as surrogate end-points for overall survival in anti-programmed death-1 and anti-programmed death ligand 1 trials","volume":"106","author":"Nie","year":"2019","journal-title":"Eur J Cancer"},{"key":"key20211223115343472_ref1-bib124","doi-asserted-by":"publisher","first-page":"5505","DOI":"10.2147\/CMAR.S174063","article-title":"Does the use of targeted agents in advanced gastroesophageal cancer increase complete response? A meta-analysis of 18 randomized controlled trials","volume":"10","author":"Pang","year":"2018","journal-title":"Cancer Manag Res"},{"key":"key20211223115343472_ref1-bib125","doi-asserted-by":"publisher","first-page":"E19","DOI":"10.1684\/bdc.2014.1934","article-title":"What is an active regimen in carcinoma of unknown primary sites? Analysis of correlation between activity endpoints reported in phase II trials. Correlation of activity endpoints in phase II trials","volume":"101","author":"Penel","year":"2014","journal-title":"Bull Cancer"},{"key":"key20211223115343472_ref1-bib126","doi-asserted-by":"publisher","first-page":"385","DOI":"10.1016\/j.clgc.2013.07.012","article-title":"Surrogate end points and postprogression survival in renal cell carcinoma: an analysis of first-line trials with targeted therapies","volume":"11","author":"Petrelli","year":"2013","journal-title":"Clin Genitourin Cancer"},{"key":"key20211223115343472_ref1-bib127","doi-asserted-by":"publisher","first-page":"776","DOI":"10.1007\/s12032-013-0776-4","article-title":"Surrogate endpoints in metastatic breast cancer treated with targeted therapies: an analysis of the first-line phase III trials","volume":"31","author":"Petrelli","year":"2014","journal-title":"Med Oncol"},{"key":"key20211223115343472_ref1-bib128","doi-asserted-by":"publisher","first-page":"522","DOI":"10.1001\/jamaoncol.2017.5236","article-title":"Defining the most appropriate primary end point in phase 2 trials of immune checkpoint inhibitors for advanced solid cancers: a systematic review and meta-analysis","volume":"4","author":"Ritchie","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20211223115343472_ref1-bib129","doi-asserted-by":"publisher","first-page":"324","DOI":"10.1016\/j.ygyno.2010.01.040","article-title":"Assessment of tumor response as a surrogate endpoint of survival in recurrent\/platinum-resistant ovarian carcinoma: a Gynecologic Oncology Group study","volume":"117","author":"Rose","year":"2010","journal-title":"Gynecol Oncol"},{"key":"key20211223115343472_ref1-bib130","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.ejca.2017.09.018","article-title":"Response rate as a potential surrogate for survival and efficacy in patients treated with novel immune checkpoint inhibitors: a meta-regression of randomised prospective studies","volume":"86","author":"Roviello","year":"2017","journal-title":"Eur J Cancer"},{"key":"key20211223115343472_ref1-bib131","doi-asserted-by":"publisher","first-page":"731","DOI":"10.1023\/a:1008303921033","article-title":"Progressive disease rate as a surrogate endpoint of phase II trials for non-small-cell lung cancer","volume":"10","author":"Sekine","year":"1999","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib132","doi-asserted-by":"publisher","first-page":"552","DOI":"10.1200\/JCO.2016.70.8651","article-title":"Thirty-month complete response as a surrogate end point in first-line follicular lymphoma therapy: an individual patient-level analysis of multiple randomized trials","volume":"35","author":"Shi","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib133","doi-asserted-by":"publisher","first-page":"362","DOI":"10.1007\/s10120-013-0274-6","article-title":"Correlation between overall survival and other endpoints in clinical trials of second-line chemotherapy for patients with advanced gastric cancer","volume":"17","author":"Shitara","year":"2014","journal-title":"Gastric Cancer"},{"key":"key20211223115343472_ref1-bib134","doi-asserted-by":"publisher","first-page":"1927","DOI":"10.1016\/j.jtho.2016.07.017","article-title":"Relationship between overall survival and response or progression-free survival in advanced non-small cell lung cancer patients treated with anti-PD-1\/PD-L1 antibodies","volume":"11","author":"Shukuya","year":"2016","journal-title":"J Thorac Oncol"},{"key":"key20211223115343472_ref1-bib135","doi-asserted-by":"publisher","first-page":"44","DOI":"10.1016\/j.ygyno.2017.03.515","article-title":"Objective response rate is a possible surrogate endpoint for survival in patients with advanced, recurrent ovarian cancer","volume":"146","author":"Siddiqui","year":"2017","journal-title":"Gynecol Oncol"},{"key":"key20211223115343472_ref1-bib136","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1158\/1078-0432.CCR-12-2502","article-title":"Evaluation of progression-free survival as a surrogate endpoint for survival in chemotherapy and targeted agent metastatic colorectal cancer trials","volume":"19","author":"Sidhu","year":"2013","journal-title":"Clin Cancer Res"},{"key":"key20211223115343472_ref1-bib137","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1186\/s12885-019-5268-2","article-title":"Surrogacy of intermediate endpoints for overall survival in randomized controlled trials of first-line treatment for advanced soft tissue sarcoma in the pre- and post-pazopanib era: a meta-analytic evaluation","volume":"19","author":"Tanaka","year":"2019","journal-title":"BMC Cancer"},{"key":"key20211223115343472_ref1-bib138","doi-asserted-by":"publisher","first-page":"4562","DOI":"10.1200\/JCO.2006.08.1935","article-title":"Surrogate end points for median overall survival in metastatic colorectal cancer: literature-based analysis from 39 randomized controlled trials of first-line chemotherapy","volume":"25","author":"Tang","year":"2007","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib139","doi-asserted-by":"publisher","first-page":"994","DOI":"10.1097\/JTO.0b013e3181a94a2f","article-title":"Response rate is associated with prolonged survival in patients with advanced non-small cell lung cancer treated with gefitinib or erlotinib","volume":"4","author":"Tsujino","year":"2009","journal-title":"J Thorac Oncol"},{"key":"key20211223115343472_ref1-bib140","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1093\/annonc\/mdp588","article-title":"Is response rate increment obtained by molecular targeted agents related to survival benefit in the phase III trials of advanced cancer?","volume":"21","author":"Tsujino","year":"2010","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib141","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1097\/PPO.0b013e3181b9d37b","article-title":"Stable disease is not preferentially observed with targeted therapies and as currently defined has limited value in drug development","volume":"15","author":"Vidaurre","year":"2009","journal-title":"Cancer J"},{"key":"key20211223115343472_ref1-bib142","doi-asserted-by":"publisher","first-page":"379","DOI":"10.1097\/PPO.0b013e3181bef8cd","article-title":"Progression-free survival is simply a measure of a drug\u2019s effect while administered and is not a surrogate for overall survival","volume":"15","author":"Wilkerson","year":"2009","journal-title":"Cancer J"},{"key":"key20211223115343472_ref1-bib143","doi-asserted-by":"publisher","first-page":"1469","DOI":"10.1200\/JCO.2015.64.3437","article-title":"Evolution of randomized trials in advanced\/metastatic soft tissue sarcoma: end point selection, surrogacy, and quality of reporting","volume":"34","author":"Zer","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib144","doi-asserted-by":"publisher","first-page":"669","DOI":"10.1208\/s12248-017-0056-x","article-title":"Assessment of correlation between early and late efficacy endpoints to identify potential surrogacy relationships in non-Hodgkin lymphoma: a literature-based meta-analysis of 108 phase II and phase III studies","volume":"19","author":"Zhu","year":"2017","journal-title":"AAPS J"},{"key":"key20211223115343472_ref1-bib145","doi-asserted-by":"publisher","first-page":"113","DOI":"10.1016\/j.lungcan.2018.12.023","article-title":"The impact of high PD-L1 expression on the surrogate endpoints and clinical outcomes of anti-PD-1\/PD-L1 antibodies in non-small cell lung cancer","volume":"128","author":"Ito","year":"2019","journal-title":"Lung Cancer"},{"key":"key20211223115343472_ref1-bib146","unstructured":"Bujkiewicz S, Achana F, Papanikos T, Riley RD, Abrams KR. NICE DSU Technical Support Document 20: Multivariate Meta-analysis of Summary Data for Combining Treatment Effects on Correlated Outcomes and Evaluating Surrogate Endpoints. Report by The Decision Support Unit. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2019."},{"key":"key20211223115343472_ref1-bib147","doi-asserted-by":"publisher","first-page":"3322","DOI":"10.1002\/sim.8187","article-title":"Bivariate network meta-analysis for surrogate endpoint evaluation","volume":"38","author":"Bujkiewicz","year":"2019","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib148","doi-asserted-by":"publisher","first-page":"165","DOI":"10.1177\/0272989X20980327","article-title":"Exploring heterogeneity in histology-independent technologies and the implications for cost-effectiveness","volume":"41","author":"Murphy","year":"2021","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib149","doi-asserted-by":"publisher","first-page":"279","DOI":"10.1177\/0272989X8800800409","article-title":"Focusing technology assessment using medical decision theory","volume":"8","author":"Phelps","year":"1988","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib150","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1002\/hec.788","article-title":"Stratified cost-effectiveness analysis: a framework for establishing efficient limited use criteria","volume":"12","author":"Coyle","year":"2003","journal-title":"Health Econ"},{"key":"key20211223115343472_ref1-bib151","doi-asserted-by":"publisher","first-page":"951","DOI":"10.1177\/0272989X14538705","article-title":"The value of heterogeneity for cost-effectiveness subgroup analysis: conceptual framework and application","volume":"34","author":"Espinoza","year":"2014","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib152","doi-asserted-by":"publisher","first-page":"112","DOI":"10.1177\/0272989X06297393","article-title":"Value of information on preference heterogeneity and individualized care","volume":"27","author":"Basu","year":"2007","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib153","volume-title":"Cancer Research UK Policy Statement: Patient Access to Molecular Diagnostics and Targeted Medicines in England","author":"Cancer Research","year":"2018"},{"key":"key20211223115343472_ref1-bib154","volume-title":"The BUGS Book","author":"Lunn","year":"2013"},{"key":"key20211223115343472_ref1-bib155","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v012.i03","article-title":"R2WinBUGS: a package for running WinBUGS from R","volume":"12","author":"Sturtz","year":"2005","journal-title":"J Stat Softw"},{"key":"key20211223115343472_ref1-bib156","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1080\/10618600.1998.10474787","article-title":"General methods for monitoring convergence of iterative simulations","volume":"7","author":"Brooks","year":"1998","journal-title":"J Comput Graph Stat"},{"key":"key20211223115343472_ref1-bib157","doi-asserted-by":"publisher","first-page":"457","DOI":"10.1214\/ss\/1177011136","article-title":"Inferences from iterative simulation using multiple sequences","volume":"7","author":"Gelman","year":"1992","journal-title":"Stat Sci"},{"key":"key20211223115343472_ref1-bib158","unstructured":"National Institute for Health and Care Excellence (NICE). Larotrectinib for Treating NTRK Fusion-positive Advanced Solid Tumours. Technology Appraisal Guidance [TA630]. London: NICE; 2019."},{"key":"key20211223115343472_ref1-bib159","first-page":"223","article-title":"RET\/NTRK1 rearrangements in thyroid gland tumors of the papillary carcinoma family: correlation with clinicopathological features","volume":"4","author":"Bongarzone","year":"1998","journal-title":"Clin Cancer Res"},{"key":"key20211223115343472_ref1-bib160","doi-asserted-by":"publisher","first-page":"1097","DOI":"10.1002\/cncr.29887","article-title":"NTRK fusion oncogenes in pediatric papillary thyroid carcinoma in northeast United States","volume":"122","author":"Prasad","year":"2016","journal-title":"Cancer"},{"key":"key20211223115343472_ref1-bib161","doi-asserted-by":"publisher","DOI":"10.1002\/pbc.26925","article-title":"ETV6\u2013NTRK3 in congenital mesoblastic nephroma: a report of the SIOP\/GPOH nephroblastoma study","volume":"65","author":"Vokuhl","year":"2018","journal-title":"Pediatr Blood Cancer"},{"key":"key20211223115343472_ref1-bib162","volume-title":"NICE DSU Technical Support Document 18: Methods for Population-adjusted Indirect Comparisons in Submissions to NICE","author":"Phillippo","year":"2016"},{"key":"key20211223115343472_ref1-bib163","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1186\/s12962-017-0071-x","article-title":"Estimating outcomes and cost effectiveness using a single-arm clinical trial: ofatumumab for double-refractory chronic lymphocytic leukemia","volume":"15","author":"Hatswell","year":"2017","journal-title":"Cost Eff Resour Alloc"},{"key":"key20211223115343472_ref1-bib164","doi-asserted-by":"publisher","first-page":"1563","DOI":"10.1177\/0962280219826609","article-title":"Creating historical controls using data from a previous line of treatment \u2013 two non-standard approaches","volume":"29","author":"Hatswell","year":"2020","journal-title":"Stat Methods Med Res"},{"key":"key20211223115343472_ref1-bib165","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1016\/j.jmoldx.2019.03.008","article-title":"Detection of tumor NTRK gene fusions to identify patients who may benefit from tyrosine kinase (TRK) inhibitor therapy","volume":"21","author":"Hsiao","year":"2019","journal-title":"J Mol Diagn"},{"key":"key20211223115343472_ref1-bib166","volume-title":"National Genomic Test Directory","author":"NHS England","year":"2019"},{"key":"key20211223115343472_ref1-bib167","doi-asserted-by":"publisher","first-page":"789","DOI":"10.1038\/nm1087","article-title":"Cancer genes and the pathways they control","volume":"10","author":"Vogelstein","year":"2004","journal-title":"Nat Med"},{"key":"key20211223115343472_ref1-bib168","doi-asserted-by":"publisher","first-page":"171","DOI":"10.1016\/j.critrevonc.2018.11.008","article-title":"Complexity of genome sequencing and reporting: next generation sequencing (NGS) technologies and implementation of precision medicine in real life","volume":"133","author":"Morganti","year":"2019","journal-title":"Crit Rev Oncol Hematol"},{"key":"key20211223115343472_ref1-bib169","doi-asserted-by":"publisher","first-page":"572","DOI":"10.1038\/nrc3299","article-title":"From cancer genomes to oncogenic drivers, tumour dependencies and therapeutic targets","volume":"12","author":"Eifert","year":"2012","journal-title":"Nat Rev Cancer"},{"key":"key20211223115343472_ref1-bib170","doi-asserted-by":"publisher","first-page":"929","DOI":"10.1200\/JCO.2016.70.7539","article-title":"Clinical and technical aspects of genomic diagnostics for precision oncology","volume":"35","author":"Sheikine","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib171","doi-asserted-by":"publisher","first-page":"3163","DOI":"10.1158\/0008-5472.CAN-19-0372","article-title":"Detection of NTRK fusions: merits and limitations of current diagnostic platforms","volume":"79","author":"Solomon","year":"2019","journal-title":"Cancer Res"},{"key":"key20211223115343472_ref1-bib172","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1136\/jclinpath-2018-205679","article-title":"Testing algorithm for identification of patients with TRK fusion cancer","volume":"72","author":"Penault-Llorca","year":"2019","journal-title":"J Clin Pathol"},{"key":"key20211223115343472_ref1-bib173","doi-asserted-by":"crossref","first-page":"91","DOI":"10.1016\/B978-0-12-800206-3.00005-7","volume-title":"Epigenetic Cancer Therapy","author":"Wright","year":"2015"},{"key":"key20211223115343472_ref1-bib174","doi-asserted-by":"publisher","first-page":"1417","DOI":"10.1093\/annonc\/mdz204","article-title":"ESMO recommendations on the standard methods to detect NTRK fusions in daily practice and clinical research","volume":"30","author":"Marchi\u00f2","year":"2019","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib175","doi-asserted-by":"publisher","first-page":"35809","DOI":"10.18632\/oncotarget.26260","article-title":"Comprehensive genomic profiling identifies novel NTRK fusions in neuroendocrine tumors","volume":"9","author":"Sigal","year":"2018","journal-title":"Oncotarget"},{"key":"key20211223115343472_ref1-bib176","doi-asserted-by":"publisher","DOI":"10.1200\/PO.18.00183","article-title":"Analysis of NTRK alterations in pan-cancer adult and pediatric malignancies: implications for NTRK-targeted therapeutics","volume":"2018","author":"Okamura","year":"2018","journal-title":"JCO Precis Oncol"},{"key":"key20211223115343472_ref1-bib177","unstructured":"U.S. Food and Drug Administration (FDA), Center for Drug Evaluation and Research. NDA Multidisciplinary Review and Evaluation NDA 210861 and NDA 211710 VITRAKVI (Larotrectinib). Silver Spring, MD: FDA; 2016."},{"key":"key20211223115343472_ref1-bib178","doi-asserted-by":"publisher","first-page":"e000023","DOI":"10.1136\/esmoopen-2015-000023","article-title":"NTRK gene fusions as novel targets of cancer therapy across multiple tumour types","volume":"1","author":"Amatu","year":"2016","journal-title":"ESMO Open"},{"key":"key20211223115343472_ref1-bib179","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1007\/s00428-018-2411-4","article-title":"Validation of the Oncomine\u2122 focus panel for next-generation sequencing of clinical tumour samples","volume":"473","author":"Williams","year":"2018","journal-title":"Virchows Arch"},{"key":"key20211223115343472_ref1-bib180","doi-asserted-by":"publisher","first-page":"38","DOI":"10.1038\/s41379-019-0324-7","article-title":"NTRK fusion detection across multiple assays and 33,997 cases: diagnostic implications and pitfalls","volume":"33","author":"Solomon","year":"2020","journal-title":"Mod Pathol"},{"key":"key20211223115343472_ref1-bib181","doi-asserted-by":"publisher","first-page":"152","DOI":"10.1002\/gcc.20028","article-title":"A fluorescence in situ hybridization study of ETV6\u2013NTRK3 fusion gene in secretory breast carcinoma","volume":"40","author":"Makretsov","year":"2004","journal-title":"Genes Chromosomes Cancer"},{"key":"key20211223115343472_ref1-bib182","unstructured":"Scottish Science Advisory Council (SSAC). Informing the Future of Genomic Medicine in Scotland. Edinburgh: SSAC; 2019."},{"key":"key20211223115343472_ref1-bib183","unstructured":"Canadian Agency for Drugs and Techonologies in Health (CADTH). Larotrectinib (Vitrakvi) for Neurotrophic Tyrosine Receptor Kinase (NTRK) Positive Solid Tumours: Pan-Canadian Oncology Drug Review. Final Economic Guidance Report. Toronto, ON: CADTH; 2019."},{"key":"key20211223115343472_ref1-bib184","volume-title":"Partitioned Survival Analysis for Decision Modelling in Health Care: A Critical Review","author":"Woods","year":"2017"},{"key":"key20211223115343472_ref1-bib185","volume-title":"NICE DSU Technical Support Document 14: Survival Analysis for Economic Evaluations alongside Clinical Trials - Extrapolation with Patient-level Data","author":"Latimer","year":"2011"},{"key":"key20211223115343472_ref1-bib186","doi-asserted-by":"publisher","first-page":"1129","DOI":"10.1007\/s40273-019-00806-4","article-title":"Estimating lifetime benefits associated with immuno-oncology therapies: challenges and approaches for overall survival extrapolations","volume":"37","author":"Ouwens","year":"2019","journal-title":"PharmacoEconomics"},{"key":"key20211223115343472_ref1-bib187","doi-asserted-by":"publisher","first-page":"205","DOI":"10.1016\/j.jval.2010.08.001","article-title":"Model averaging in the presence of structural uncertainty about treatment effects: influence on treatment decision and expected value of information","volume":"14","author":"Price","year":"2011","journal-title":"Value Health"},{"key":"key20211223115343472_ref1-bib188","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1177\/0272989X11406986","article-title":"A framework for addressing structural uncertainty in decision models","volume":"31","author":"Jackson","year":"2011","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib189","volume-title":"Co-dependent and Hybrid Technologies","author":"Australian Government Department of Health","year":"2017"},{"key":"key20211223115343472_ref1-bib190","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1177\/0272989X17749829","article-title":"Establishing the value of diagnostic and prognostic tests in health technology assessment","volume":"38","author":"Soares","year":"2018","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib191","doi-asserted-by":"publisher","first-page":"513","DOI":"10.1200\/JCO.18.00573","article-title":"TRK fusion cancers in children: a clinical review and recommendations for screening","volume":"37","author":"Albert","year":"2019","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib192","doi-asserted-by":"publisher","first-page":"68","DOI":"10.1177\/0272989X98018002S09","article-title":"Net health benefits: a new framework for the analysis of uncertainty in cost-effectiveness analysis","volume":"18","author":"Stinnett","year":"1998","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib193","doi-asserted-by":"crossref","DOI":"10.1093\/oso\/9780198526629.001.0001","volume-title":"Decision Modelling for Health Economic Evaluation","author":"Briggs","year":"2006"},{"issue":"7","key":"key20211223115343472_ref1-bib194","doi-asserted-by":"publisher","DOI":"10.3310\/hta21070","article-title":"The assessment and appraisal of regenerative medicines and cell therapy products: an exploration of methods for review, economic evaluation and appraisal","volume":"21","author":"Hettle","year":"2017","journal-title":"Health Technol Assess"},{"key":"key20211223115343472_ref1-bib195","unstructured":"Grimm S, Strong M, Brennan A, Wailoo A. Framework for Analysing Risk in Health Technology Assessments and Its Application to Managed Entry Agreements. Report by the Decision Support Unit. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2016."},{"key":"key20211223115343472_ref1-bib196","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1016\/S0167-6296(98)00039-3","article-title":"The irrelevance of inference: a decision-making approach to the stochastic evaluation of health care technologies","volume":"18","author":"Claxton","year":"1999","journal-title":"J Health Econ"},{"key":"key20211223115343472_ref1-bib197","doi-asserted-by":"publisher","first-page":"885","DOI":"10.1016\/j.jval.2016.03.2003","article-title":"A comprehensive algorithm for approval of health technologies with, without, or only in research: the key principles for informing coverage decisions","volume":"19","author":"Claxton","year":"2016","journal-title":"Value Health"},{"key":"key20211223115343472_ref1-bib198","doi-asserted-by":"publisher","first-page":"207","DOI":"10.1177\/0272989X04263162","article-title":"Expected value of sample information calculations in medical decision modeling","volume":"24","author":"Ades","year":"2004","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib199","unstructured":"NHS England Cancer Drugs Fund Team. Appraisal and Funding of Cancer Drugs from July 2016 (Including the New Cancer Drugs Fund): A New Deal for Patients, Taxpayers and Industry. London: NHS England; 2016."},{"key":"key20211223115343472_ref1-bib200","volume-title":"Pharmaceutical Pricing: Early Access, The Cancer Drugs Fund and the Role of NICE","author":"Claxton","year":"2016"},{"key":"key20211223115343472_ref1-bib201","doi-asserted-by":"publisher","first-page":"i5090","DOI":"10.1136\/bmj.i5090","article-title":"Cancer Drugs Fund requires further reform","volume":"354","author":"Grieve","year":"2016","journal-title":"BMJ"},{"key":"key20211223115343472_ref1-bib202","doi-asserted-by":"publisher","first-page":"393","DOI":"10.1186\/s12913-018-3162-2","article-title":"Will the reformed Cancer Drugs Fund address the most common types of uncertainty? An analysis of NICE cancer drug appraisals","volume":"18","author":"Morrell","year":"2018","journal-title":"BMC Health Serv Res"},{"key":"key20211223115343472_ref1-bib203","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1177\/0272989X13505910","article-title":"Estimating multiparameter partial expected value of perfect information from a probabilistic sensitivity analysis sample: a nonparametric regression approach","volume":"34","author":"Strong","year":"2014","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib204","doi-asserted-by":"publisher","first-page":"570","DOI":"10.1177\/0272989X15575286","article-title":"Estimating the expected value of sample information using the probabilistic sensitivity analysis sample: a fast, nonparametric regression-based method","volume":"35","author":"Strong","year":"2015","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib205","doi-asserted-by":"publisher","first-page":"1791","DOI":"10.1002\/sim.2069","article-title":"The value of information and optimal clinical trial design","volume":"24","author":"Willan","year":"2005","journal-title":"Stat Med"},{"key":"key20211223115343472_ref1-bib206","doi-asserted-by":"crossref","unstructured":"National Institute for Health and Care Excellence (NICE). Guide to the Processes of Technology Appraisal. London: NICE; 2018.","DOI":"10.1016\/j.jval.2018.09.1189"},{"key":"key20211223115343472_ref1-bib207","doi-asserted-by":"publisher","first-page":"930","DOI":"10.1177\/0272989X17702379","article-title":"New metrics for economic evaluation in the presence of heterogeneity: focusing on evaluating policy alternatives rather than treatment alternatives","volume":"37","author":"Kim","year":"2017","journal-title":"Med Decis Making"},{"key":"key20211223115343472_ref1-bib208","volume-title":"Methods for the Economic Evaluation of Health Care Programmes","author":"Drummond","year":"2015"},{"key":"key20211223115343472_ref1-bib209","doi-asserted-by":"crossref","first-page":"545","DOI":"10.1002\/hec.1249","article-title":"OFT, VBP: QED?","volume":"16","author":"Claxton","year":"2007","journal-title":"Health Econ"},{"key":"key20211223115343472_ref1-bib210","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1002\/hec.3467","article-title":"Characterising uncertainty in the assessment of medical devices and determining future research needs","volume":"26","author":"Rothery","year":"2017","journal-title":"Health Econ"},{"key":"key20211223115343472_ref1-bib211","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1186\/s13063-015-1023-4","article-title":"A literature review on the representativeness of randomized controlled trial samples and implications for the external validity of trial results","volume":"16","author":"Kennedy-Martin","year":"2015","journal-title":"Trials"},{"key":"key20211223115343472_ref1-bib212","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab with Carboplatin and Paclitaxel for Untreated Metastatic Squamous Non-small-cell Lung Cancer. Technology Appraisal Guidance [TA600]. London: NICE; 2019."},{"key":"key20211223115343472_ref1-bib213","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for Untreated PD-L1-positive Locally Advanced or Metastatic Urothelial Cancer when Cisplatin is Unsuitable. Technology Appraisal [TA674]. London: NICE; 2018."},{"key":"key20211223115343472_ref1-bib214","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for Untreated Metastatic or Unresectable Recurrent Squamous Cell Head and Neck Cancer. Technology Appraisal Guidance [TA661]. London: NICE; 2020. URL: www.nice.org.uk\/guidance\/TA661 (accessed 20 February 2020)."},{"key":"key20211223115343472_ref1-bib215","volume-title":"Workshop on Site and Histology \u2013 Independent Indications of Oncology","author":"European Medicines Agency","year":"2018"},{"key":"key20211223115343472_ref1-bib216","volume-title":"Workshop on Single-arm Studies in Oncology","author":"European Medicines Agency","year":"2016"},{"key":"key20211223115343472_ref1-bib217","volume-title":"Developing Targeted Therapies in Low-Frequency Molecular Subsets of a Disease","author":"US Food and Drug Administration","year":"2018"},{"key":"key20211223115343472_ref1-bib218","volume-title":"Master Protocols: Efficient Clinical Trial Design Strategies to Expedite Development of Oncology Drugs and Biologics","author":"US Food and Drug Administration","year":"2018"},{"key":"key20211223115343472_ref1-bib219","volume-title":"Guidance for Industry: Expedited Programs for Serious Conditions \u2013 Drugs and Biologics","author":"US Department of Health and Human Services, U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Center for Biologics Evaluation and Research","year":"2014"},{"key":"key20211223115343472_ref1-bib220","volume-title":"Table of Surrogate Endpoints That Were the Basis of Drug Approval or Licensure","author":"Food and Drug Administration"},{"key":"key20211223115343472_ref1-bib221","volume-title":"Clinical Trial Endpoints for the Approval of Cancer Drugs and Biologics Guidance for Industry","author":"Food and Drug Administration (FDA)","year":"2018"},{"key":"key20211223115343472_ref1-bib222","volume-title":"Tissue Agnostic Therapies in Oncology: Regulatory Considerations for Orphan Drug Designation","author":"US Food and Drug Administration"},{"key":"key20211223115343472_ref1-bib223","volume-title":"Essential Considerations for Successful Qualification of Novel Methodologies","author":"European Medicines Agency","year":"2017"},{"key":"key20211223115343472_ref1-bib224","volume-title":"Biostatistics","author":"European Medicines Agency","year":"2021"},{"key":"key20211223115343472_ref1-bib225","volume-title":"Predictive Biomarker-based Assay Development in the Context of Drug Development and Lifecycle","author":"European Medicines Agency","year":"2017"},{"key":"key20211223115343472_ref1-bib226","volume-title":"Guideline on the Evaluation of Anticancer Medicinal Products in Man Rev. 5","author":"European Medicines Agency","year":"2017"},{"key":"key20211223115343472_ref1-bib227","volume-title":"Appendix 4 to the Guideline on the Evaluation of Anticancer Medicinal Products in Man","author":"European Medicines Agency","year":"2015"},{"key":"key20211223115343472_ref1-bib228","unstructured":"National Institute for Health and Care Excellence (NICE). Ceritinib for Previously Treated Anaplastic Lymphoma Kinase Positive Non-Small-Cell Lung Cancer. Technology Appraisal Guidance [TA395]. London: NICE; 2016."},{"key":"key20211223115343472_ref1-bib229","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1016\/S1470-2045(15)00614-2","article-title":"Activity and safety in ceritinib in patients with ALK-rearranged non-small-cell lung cancer (ASCEND-1): updated results from the multicentre, open-label, phase 1 trial","volume":"17","author":"Kim","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib230","doi-asserted-by":"publisher","first-page":"2866","DOI":"10.1200\/JCO.2015.65.5936","article-title":"Multicenter phase II study of whole-body and intracranial activity with ceritinib in patients with ALK-rearranged non-small-cell lung cancer previously treated with chemotherapy and crizotinib: results from ASCEND-2","volume":"34","author":"Crin\u00f2","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib231","unstructured":"National Institute for Health and Care Excellence (NICE). Osimertinib for Treating Locally Advanced or Metastatic EGFR T790M Mutation-positive Non-small-cell Lung Cancer. Technology Appraisal Guidance [TA416]. London: NICE; 2016."},{"key":"key20211223115343472_ref1-bib232","doi-asserted-by":"publisher","first-page":"1288","DOI":"10.1200\/JCO.2016.70.3223","article-title":"Osimertinib in pretreated T790M-positive advanced non-small-cell lung cancer: AURA study phase II extension component","volume":"35","author":"Yang","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib233","doi-asserted-by":"publisher","first-page":"1643","DOI":"10.1016\/S1470-2045(16)30508-3","article-title":"Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study","volume":"17","author":"Goss","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib234","doi-asserted-by":"publisher","first-page":"892","DOI":"10.1002\/cncr.31891","article-title":"Osimertinib in patients with T790M mutation-positive, advanced non\u2013small cell lung cancer: long-term follow-up from a pooled analysis of 2 phase 2 studies","volume":"125","author":"Ahn","year":"2019","journal-title":"Cancer"},{"key":"key20211223115343472_ref1-bib235","unstructured":"National Institute for Health and Care Excellence (NICE). Nivolumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma. Technology Appraisal Guidance [TA462]. London: NICE; 2017."},{"key":"key20211223115343472_ref1-bib236","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1016\/S1470-2045(16)30167-X","article-title":"Nivolumab for classical Hodgkin's lymphoma after failure of both autologous stem-cell transplantation and brentuximab vedotin: a multicentre, multicohort, single-arm phase 2 trial","volume":"17","author":"Younes","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib237","doi-asserted-by":"publisher","first-page":"2698","DOI":"10.1200\/JCO.2015.65.9789","article-title":"Nivolumab in patients with relapsed or refractory hematologic malignancy: preliminary results of a phase 1b study","volume":"34","author":"Lesokhin","year":"2016","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib238","unstructured":"National Institute for Health and Care Excellence (NICE). Venetoclax for Treating Chronic Lymphocytic Leukaemia. Technology Appraisal Guidance [TA487]. London: NICE; 2017."},{"key":"key20211223115343472_ref1-bib239","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1200\/JCO.2016.70.4320","article-title":"Phase I first-in-human study of venetoclax in patients with relapsed or refractory non-Hodgkin lymphoma","volume":"35","author":"Davids","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib240","doi-asserted-by":"publisher","first-page":"768","DOI":"10.1016\/S1470-2045(16)30019-5","article-title":"Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study","volume":"17","author":"Stilgenbauer","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib241","doi-asserted-by":"publisher","first-page":"1973","DOI":"10.1200\/JCO.2017.76.6840","article-title":"Venetoclax for patients with chronic lymphocytic leukemia with 17p deletion: results from the full population of a phase II pivotal trial","volume":"36","author":"Stilgenbauer","year":"2018","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib242","doi-asserted-by":"publisher","first-page":"1704","DOI":"10.1182\/blood-2017-06-788133","article-title":"Venetoclax for patients with chronic lymphocytic leukemia who progressed during or after idelalisib therapy","volume":"131","author":"Coutre","year":"2018","journal-title":"Blood"},{"key":"key20211223115343472_ref1-bib243","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1016\/S1470-2045(17)30909-9","article-title":"Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial","volume":"19","author":"Jones","year":"2018","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib244","unstructured":"National Institute for Health and Care Excellence (NICE). Atezolizumab for Untreated PD-L1-Positive Locally Advanced or Metastatic Urothelial Cancer When Cisplatin is Unsuitable. Technology Appraisal Guidance [TA492]. London: NICE; 2018."},{"key":"key20211223115343472_ref1-bib245","doi-asserted-by":"publisher","first-page":"67","DOI":"10.1016\/S0140-6736(16)32455-2","article-title":"Atezolizumab as first-line treatment in cisplatin-ineligible patients with locally advanced and metastatic urothelial carcinoma: a single-arm, multicentre, phase 2 trial","volume":"389","author":"Balar","year":"2017","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib246","doi-asserted-by":"publisher","first-page":"3044","DOI":"10.1093\/annonc\/mdx518","article-title":"Atezolizumab in platinum-treated locally advanced or metastatic urothelial carcinoma: post-progression outcomes from the phase II IMvigor210 study","volume":"28","author":"Necchi","year":"2017","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib247","doi-asserted-by":"publisher","first-page":"1909","DOI":"10.1016\/S0140-6736(16)00561-4","article-title":"Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial","volume":"387","author":"Rosenberg","year":"2016","journal-title":"Lancet"},{"key":"key20211223115343472_ref1-bib248","unstructured":"National Institute for Health and Care Excellence (NICE). Daratumumab Monotherapy for Treating Relapsed and Refractory Multiple Myeloma. Technology Appraisal Guidance [TA510]. London: NICE; 2018."},{"key":"key20211223115343472_ref1-bib249","doi-asserted-by":"publisher","first-page":"1551","DOI":"10.1016\/S0140-6736(15)01120-4","article-title":"Daratumumab monotherapy in patients with treatment-refractory multiple myeloma (SIRIUS): an open-label, randomised, phase 2 trial","volume":"387","author":"Lonial","year":"2016","journal-title":"Lancet"},{"key":"key20211223115343472_ref1-bib250","doi-asserted-by":"publisher","first-page":"1207","DOI":"10.1056\/NEJMoa1506348","article-title":"Targeting CD38 with daratumumab monotherapy in multiple myeloma","volume":"373","author":"Lokhorst","year":"2015","journal-title":"New Engl J Med"},{"key":"key20211223115343472_ref1-bib251","doi-asserted-by":"publisher","first-page":"37","DOI":"10.1182\/blood-2016-03-705210","article-title":"Clinical efficacy of daratumumab monotherapy in patients with heavily pretreated relapsed or refractory multiple myeloma","volume":"128","author":"Usmani","year":"2016","journal-title":"Blood"},{"key":"key20211223115343472_ref1-bib252","unstructured":"National Institute for Health and Care Excellence (NICE). Avelumab for Treating Metastatic Merkel Cell Carcinoma. Technology Appraisal Guidance [TA517]. London: NICE; 2017."},{"key":"key20211223115343472_ref1-bib253","doi-asserted-by":"publisher","first-page":"1374","DOI":"10.1016\/S1470-2045(16)30364-3","article-title":"Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial","volume":"17","author":"Kaufman","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib254","doi-asserted-by":"publisher","first-page":"e180077","DOI":"10.1001\/jamaoncol.2018.0077","article-title":"Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial","volume":"4","author":"D\u2019Angelo","year":"2018","journal-title":"JAMA Oncol"},{"key":"key20211223115343472_ref1-bib255","unstructured":"National Institute for Health and Care Excellence (NICE). Crizotinib for Treating ROS1-positive Advanced Non-small-cell Lung Cancer. Technology Appraisal Guidance [TA529]. London: NICE; 2018."},{"key":"key20211223115343472_ref1-bib256","doi-asserted-by":"publisher","first-page":"1963","DOI":"10.1056\/NEJMoa1406766","article-title":"Crizotinib in ROS1-rearranged non\u2013small-cell lung cancer","volume":"371","author":"Shaw","year":"2014","journal-title":"New Engl J Med"},{"key":"key20211223115343472_ref1-bib257","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1093\/annonc\/mdz131","article-title":"Crizotinib in ROS1-rearranged advanced non-small-cell lung cancer (NSCLC): updated results, including overall survival, from PROFILE 1001","volume":"30","author":"Shaw","year":"2019","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib258","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for Treating Relapsed or Refractory Classical Hodgkin Lymphoma. Technology Appraisal Guidance [TA540]. London: NICE; 2018."},{"key":"key20211223115343472_ref1-bib259","doi-asserted-by":"publisher","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Phase II study of the efficacy and safety of pembrolizumab for relapsed\/refractory classic Hodgkin lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib260","unstructured":"National Institute for Health and Care Excellence (NICE). Brigatinib for Treating ALK-positive Non-small-cell Lung Cancer after Crizotinib. Technology Appraisal Guidance [TA571]. London: NICE; 2019."},{"key":"key20211223115343472_ref1-bib261","doi-asserted-by":"publisher","first-page":"2490","DOI":"10.1200\/JCO.2016.71.5904","article-title":"Brigatinib in patients with crizotinib-refractory anaplastic lymphoma kinase-positive non-small-cell lung cancer: a randomized, multicenter phase II trial","volume":"35","author":"Kim","year":"2017","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib262","doi-asserted-by":"publisher","first-page":"1683","DOI":"10.1016\/S1470-2045(16)30392-8","article-title":"Activity and safety of brigatinib in ALK-rearranged non-small-cell lung cancer and other malignancies: a single-arm, open-label, phase 1\/2 trial","volume":"17","author":"Gettinger","year":"2016","journal-title":"Lancet Oncol"},{"key":"key20211223115343472_ref1-bib263","doi-asserted-by":"publisher","first-page":"163","DOI":"10.1007\/s40273-016-0460-6","article-title":"Economic evaluations of pharmaceuticals granted a marketing authorisation without the results of randomised trials: a systematic review and taxonomy","volume":"35","author":"Hatswell","year":"2017","journal-title":"PharmacoEconomics"},{"key":"key20211223115343472_ref1-bib264","unstructured":"Faria R, Hernandez Alava M, Manca A, Wailoo AJ. The Use of Observational Data to Inform Estimates of Treatment Effectiveness for Technology Appraisal: Methods for Comparative Individual Patient Data. Report by the Decision Support Unit. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2015."},{"key":"key20211223115343472_ref1-bib265","unstructured":"Bell H, Wailoo A, Hernandez M, Grieve R, Faria R, Gibson L, et al. The Use of Real World Data for the Estimation of Treatment Effects in NICE Decision Making. Report by the Decision Support Unit. Sheffield: Decision Support Unit, ScHARR, University of Sheffield; 2016."},{"key":"key20211223115343472_ref1-bib266","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1007\/s40273-019-00801-9","article-title":"Accounting for capacity constraints in economic evaluations of precision medicine: a systematic review","volume":"37","author":"Wright","year":"2019","journal-title":"PharmacoEconomics"},{"key":"key20211223115343472_ref1-bib267","doi-asserted-by":"publisher","first-page":"743","DOI":"10.1007\/s11605-014-2726-7","article-title":"The rise in appendiceal cancer incidence: 2000\u20132009","volume":"19","author":"Marmor","year":"2015","journal-title":"J Gastrointest Surg"},{"key":"key20211223115343472_ref1-bib268","volume-title":"Western European Countries 2020","author":"World Population Review","year":"2019"},{"key":"key20211223115343472_ref1-bib269","volume-title":"Cancer Registration Statistics, England: 2017","author":"Office for National Statistics","year":"2019"},{"key":"key20211223115343472_ref1-bib270","volume-title":"Breast Cancer Incidence by Stage at Diagnosis","author":"Cancer Research","year":"2014"},{"key":"key20211223115343472_ref1-bib271","volume-title":"National Cancer Intelligence Network. Rare and Less Common Cancers: Incidence and Mortality in England, 2010 to 2013","author":"Coombes","year":"2015"},{"key":"key20211223115343472_ref1-bib272","doi-asserted-by":"publisher","first-page":"10573","DOI":"10.3748\/wjg.v21.i37.10573","article-title":"Biomarkers for the early diagnosis of hepatocellular carcinoma","volume":"21","author":"Tsuchiya","year":"2015","journal-title":"World J Gastroenterol"},{"key":"key20211223115343472_ref1-bib273","doi-asserted-by":"publisher","first-page":"i3590","DOI":"10.1136\/bmj.i3590","article-title":"Colorectal adenocarcinoma: risks, prevention and diagnosis","volume":"354","author":"Thrumurthy","year":"2016","journal-title":"BMJ"},{"key":"key20211223115343472_ref1-bib274","volume-title":"Bowel Cancer Incidence by Stage at Diagnosis","author":"Cancer Research","year":"2016"},{"key":"key20211223115343472_ref1-bib275","doi-asserted-by":"publisher","first-page":"364","DOI":"10.1186\/1471-2407-14-364","article-title":"Prevalence of gastrointestinal stromal tumour (GIST) in the United Kingdom at different therapeutic lines: an epidemiologic model","volume":"14","author":"Starczewska Amelio","year":"2014","journal-title":"BMC Cancer"},{"key":"key20211223115343472_ref1-bib276","volume-title":"Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ\u00ae): Patient Version","author":"PDQ Adult Treatment Editorial Board","year":"2020"},{"key":"key20211223115343472_ref1-bib277","doi-asserted-by":"publisher","first-page":"318","DOI":"10.1200\/JCO.2009.21.9972","article-title":"Infantile fibrosarcoma: management based on the European experience","volume":"28","author":"Orbach","year":"2010","journal-title":"J Clin Oncol"},{"key":"key20211223115343472_ref1-bib278","doi-asserted-by":"publisher","first-page":"599","DOI":"10.1097\/PAS.0b013e3181d9efcc","article-title":"Mammary analogue secretory carcinoma of salivary glands, containing the ETV6\u2013NTRK3 fusion gene: a hitherto undescribed salivary gland tumor entity","volume":"34","author":"Sk\u00e1lov\u00e1","year":"2010","journal-title":"Am J Surg Pathol"},{"key":"key20211223115343472_ref1-bib279","doi-asserted-by":"publisher","first-page":"659","DOI":"10.1097\/PAT.0000000000000322","article-title":"Mammary analogue secretory carcinoma: an evaluation of its clinicopathological and genetic characteristics","volume":"47","author":"Luk","year":"2015","journal-title":"Pathology"},{"key":"key20211223115343472_ref1-bib280","doi-asserted-by":"publisher","first-page":"188","DOI":"10.1002\/lary.24254","article-title":"Mammary analogue secretory carcinoma: update on a new diagnosis of salivary gland malignancy","volume":"124","author":"Sethi","year":"2014","journal-title":"Laryngoscope"},{"key":"key20211223115343472_ref1-bib281","volume-title":"Melanoma Skin Cancer Incidence by Stage at Diagnosis","author":"Cancer Research","year":"2016"},{"key":"key20211223115343472_ref1-bib282","unstructured":"Care Quality Improvement Department, Royal College of Physicians. National Lung Cancer Audit Annual Report 2018 (for the Audit Period 2017). London: Healthcare Quality Improvement Partnership (HQIP); 2019."},{"key":"key20211223115343472_ref1-bib283","volume-title":"Types of Pancreatic Cancer","author":"Pancreatic Cancer","year":"2018"},{"key":"key20211223115343472_ref1-bib284","volume-title":"Pancreatic Cancer Incidence by Stage at Diagnosis","author":"Cancer Research","year":"2016"},{"key":"key20211223115343472_ref1-bib285","volume-title":"Soft Tissue Sarcoma Incidence Statistics","author":"Cancer Research","year":"2010"},{"key":"key20211223115343472_ref1-bib286","volume-title":"Cancer Facts and Figures","author":"American Cancer Society","year":"2017"},{"key":"key20211223115343472_ref1-bib287","first-page":"333","article-title":"Cancers of the thyroid: overview and statistics in the United States and Oklahoma","volume":"109","author":"Deen","year":"2016","journal-title":"J Okla State Med Assoc"},{"key":"key20211223115343472_ref1-bib288","volume-title":"Cervical Cancer Incidence by Stage at Diagnosis","author":"Cancer Research","year":"2016"},{"key":"key20211223115343472_ref1-bib289","doi-asserted-by":"publisher","first-page":"e26437","DOI":"10.1002\/pbc.26437","article-title":"Congenital mesoblastic nephroma 50 years after its recognition: a narrative review","volume":"64","author":"Gooskens","year":"2017","journal-title":"Pediatr Blood Cancer"},{"key":"key20211223115343472_ref1-bib290","unstructured":"National Institute for Health and Care Excellence (NICE). Pembrolizumab for Previously Treated Oesophageal or Gastrooesophageal Junction Cancer Draft Scope. London: NICE; 2018."},{"key":"key20211223115343472_ref1-bib291","volume-title":"Oesophageal Cancer Incidence by Stage at Diagnosis","author":"Cancer Research","year":"2016"},{"key":"key20211223115343472_ref1-bib292","volume-title":"Head and Neck Cancers Statistics","author":"Cancer Research","year":"2016"},{"key":"key20211223115343472_ref1-bib293","unstructured":"Public Health England. Glioblastoma in England 2007-2011. London: Public Health England; 2016."},{"key":"key20211223115343472_ref1-bib294","doi-asserted-by":"publisher","first-page":"139","DOI":"10.1016\/j.canlet.2012.12.024","article-title":"Understanding high grade glioma: molecular mechanism, therapy and comprehensive management","volume":"331","author":"Wang","year":"2013","journal-title":"Cancer Lett"},{"key":"key20211223115343472_ref1-bib295","unstructured":"UK and Ireland Neuroendcrine Tumour Society (UKI NETS). Incidence and Prevalence of Neuroendocrine Tumours in England. London: Endocrine Abstracts; 2017."},{"key":"key20211223115343472_ref1-bib296","unstructured":"Cancer Research UK. Ovarian Cancer Incidence by Stage at Diagnosis. London: Cancer Research UK; 2016. URL: www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/ovarian-cancer\/incidence (accessed June 2019)."},{"key":"key20211223115343472_ref1-bib297","volume-title":"Analysis of the Cancer Registry Combined Database for Use with the Brain and CNS Registry","author":"Farrimond","year":"2010"},{"key":"key20211223115343472_ref1-bib298","volume-title":"Children\u2019s Cancer Incidence Statistics","author":"Cancer Research","year":"2014"},{"key":"key20211223115343472_ref1-bib299","doi-asserted-by":"publisher","first-page":"2207","DOI":"10.1016\/j.jpedsurg.2013.06.002","article-title":"Melanoma incidence rises for children and adolescents: an epidemiologic review of pediatric melanoma in the United States","volume":"48","author":"Austin","year":"2013","journal-title":"J Pediatr Surg"},{"key":"key20211223115343472_ref1-bib300","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1016\/j.mrfmmm.2005.12.013","article-title":"Molecular analysis of the RET and NTRK1 gene rearrangements in papillary thyroid carcinoma in the Polish population","volume":"599","author":"Brzezia\u0144ska","year":"2006","journal-title":"Mutat Res"},{"key":"key20211223115343472_ref1-bib301","unstructured":"Cancer Research UK. Prostate Cancer Incidence by Stage at Diagnosis. London: Cancer Research UK; 2016. URL: www.cancerresearchuk.org\/health-professional\/cancer-statistics\/statistics-by-cancer-type\/prostate-cancer\/incidence#heading-Three (accessed June 2019)."},{"key":"key20211223115343472_ref1-bib302","volume-title":"Kidney Cancer: Stages, Types and Grades","author":"Cancer Research","year":"2016"},{"key":"key20211223115343472_ref1-bib303","doi-asserted-by":"publisher","first-page":"350","DOI":"10.1016\/j.breast.2012.02.013","article-title":"Secretory carcinoma of the breast: results from the survival, epidemiology and end results database","volume":"21","author":"Horowitz","year":"2012","journal-title":"Breast"},{"key":"key20211223115343472_ref1-bib304","doi-asserted-by":"publisher","first-page":"721","DOI":"10.1002\/jso.24241","article-title":"Rare breast cancer: 246 invasive secretory carcinomas from the National Cancer Data Base","volume":"113","author":"Jacob","year":"2016","journal-title":"J Surg Oncol"},{"key":"key20211223115343472_ref1-bib305","volume-title":"The Burden of Occupational Cancer in Great Britain","author":"Rushton","year":"2010"},{"key":"key20211223115343472_ref1-bib306","volume-title":"Uterine Cancer Incidence By Stage At Diagnosis","author":"Cancer Research UK","year":"2016"},{"key":"key20211223115343472_ref1-bib307","doi-asserted-by":"publisher","first-page":"129","DOI":"10.23838\/pfm.2017.00142","article-title":"NTRK gene amplification in patients with metastatic cancer","volume":"1","author":"Lee","year":"2017","journal-title":"Precision Future Med"},{"key":"key20211223115343472_ref1-bib308","doi-asserted-by":"crossref","first-page":"E105","DOI":"10.3390\/cancers10040105","article-title":"Inhibiting TRK proteins in clinical cancer therapy","volume":"10","author":"Lange","year":"2018","journal-title":"Cancers"},{"key":"key20211223115343472_ref1-bib309","unstructured":"National Cancer Institute. Gastrointestinal Stromal Tumors Treatment (Adult) (PDQ\u00ae)\u2013Health Professional Version. Rockville, MD: National Cancer Institute; 2018. URL: www.cancer.gov\/types\/soft-tissue-sarcoma\/hp\/gist-treatment-pdq (accessed June 2019)."},{"key":"key20211223115343472_ref1-bib310","doi-asserted-by":"publisher","first-page":"ix175","DOI":"10.1093\/annonc\/mdy483.003","article-title":"Efficacy and safety of entrectinib in patients with NTRK fusion-positive tumours: pooled analysis of STARTRK-2, STARTRK-1, and ALKA-372-001","volume":"29","author":"Demetri","year":"2018","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib311","doi-asserted-by":"publisher","first-page":"v162","DOI":"10.1093\/annonc\/mdz244.007","article-title":"445PD Durability of response with larotrectinib in adult and pediatric patients with TRK fusion cancer","volume":"30","author":"Hyman","year":"2019","journal-title":"Ann Oncol"},{"key":"key20211223115343472_ref1-bib312","volume-title":"Exploring the Cost of End of Life Care","author":"Georghiou","year":"2014"}],"container-title":["Health Technology Assessment"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038391","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/publications\/hta25760\/hta25760.xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/njl-admin.nihr.ac.uk\/document\/download\/2038391","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,11,15]],"date-time":"2023-11-15T07:48:56Z","timestamp":1700034536000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.journalslibrary.nihr.ac.uk\/hta\/hta25760"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":312,"journal-issue":{"issue":"76","published-online":{"date-parts":[[2021,12]]}},"alternative-id":["10.3310\/hta25760"],"URL":"https:\/\/doi.org\/10.3310\/hta25760","relation":{},"ISSN":["1366-5278","2046-4924"],"issn-type":[{"value":"1366-5278","type":"print"},{"value":"2046-4924","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"This content has been made freely available to all.","name":"free","label":"Free to read"},{"value":"11-2018","name":"contractual_start_date","label":"Contractual start date","group":{"name":"article_history","label":"Article History"}},{"value":"3-2020","name":"editorial_review_begun","label":"Editorial review begun","group":{"name":"article_history","label":"Article History"}},{"value":"5-2021","name":"accepted_for_publication","label":"Accepted for publication","group":{"name":"article_history","label":"Article History"}}]}}